Home > UIC Law Review > Vol. 50 > Iss. 2 (2017)

UIC Law Review

Big Pharma Versus Inter Partes Review: Why the Pharmaceutical Industry Should Seek Logical Hatch-Waxman Reform over Inter Partes Review Exemption, 50 J. Marshall L. Rev. 337 (2017)

Recommended Citation

Francisco Javier Espinosa, Big Pharma Versus Inter Partes Review: Why the Pharmaceutical Industry Should Seek Logical Hatch-Waxman Reform over Inter Partes Review Exemption, 50 J. Marshall L. Rev. 337 (2017)

Download

Included in

Food and Drug Law Commons, Intellectual Property Law Commons

COinS

UIC Law Review

Big Pharma Versus Inter Partes Review: Why the Pharmaceutical Industry Should Seek Logical Hatch-Waxman Reform over Inter Partes Review Exemption, 50 J. Marshall L. Rev. 337 (2017)

Authors

Recommended Citation

Included in

Share

Search